ALZAMEND NEURO

Alzamend Neuro

Committed to the Prevention, Treatment, and Cure of Alzheimer’s Disease

Controlled Subsidiary

OWNERSHIP 52%

Alzamend Neuro

Committed to the Prevention, Treatment, and Cure of Alzheimer’s Disease

Controlled Subsidiary

OWNERSHIP 52%

Alzamend Neuro™, Inc., (“Alzamend™)” formed on February 26, 2016, is a Delaware corporation with its corporate headquarters in Tampa, Florida with nexus’ in both California and Georgia. The mission of Alzamend Neuro™ is to help the Alzheimer’s community by supporting the full product development life cycle of treatment and cures for Alzheimer’s Disease (“AD”) driven by the belief that strong support of research is the foundation for true innovation. The Company is providing hope through the commercialization of existing patented intellectual properties and know-how while simultaneously funding future treatments through advanced research and development. Alzamend Neuro’s™ underlying goal is to get a treatment or cure for Alzheimer’s to market at a reasonable cost as quickly as possible. Far too many suffer daily, patients and caregivers alike, from the burden created by the nation’s 6th leading cause of death and ‘most feared disease’. To date, 5.8 million Americans are suffering from AD, which directly impacts more than 16 million Americans who provide unpaid care for an estimated 18.5 billion hours, valued to be at $234 billion. In 2019, Alzheimer’s disease is estimated to cost the United States over $290 billion and could rise as high as $1.1 trillion by 2050 if no treatment or cure is found.

Alzamend Neuro™ is currently working to transition two therapeutics targeting Alzheimer’s disease (“AD”) from the research and preclinical stage at the University of South Florida into the clinical stage and towards full commercialization. Alzamend Neuro™ has licensed both a patented mutant-peptide immunotherapeutic (CAO22W) for use as a treatment or vaccine and a lithium based ionic cocrystal therapy (LiProSal™) that may greatly reduce or eliminate the symptoms of agitation and other endpoints for mild to moderate stage patients diagnosed with AD. There are no profound treatments today for Alzheimer’s disease. With CAO22W and LiProSal™, the Company believes that Alzamend can change that.

CAO22W

A mutant-peptide immunotherapy that is designed to be used both as a vaccine and prophylactic against Alzheimer’s disease

LiProSal

An ionic cocrystal of lithium to mitigate extreme agitation and forestall other deterioration for patients with up to moderate Alzheimer’s Disease

RESULTS

  • Acquisition of CAO22W patent license
  • Formation of Biotech company with progressive low-cost management model
  • First authorized Biotech Regulation A+ offering
  • $5.2M of capital raised
  • FDA gap analysis completed
  • Licensed second therapeutic – LiProSal

OPPORTUNITY

  • Identification of a latent university technology asset
  • Determination of value
  • Capital required to license patent and commercialize therapeutic
  • Expertise to develop, manage and market therapeutic products to the public